TORONTO, CANADA, March 09, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction, announced today that Anthony Tennyson, Chief Executive Officer, is scheduled to present at the following upcoming March 2022 investor conferences. 

34th Annual ROTH Conference

Presentation: Sunday, March 13th to Tuesday, Match 15th 

Registration: Click here 

Oppenheimer’s 32nd Annual Healthcare Conference

Presentation: Wednesday, March 15th to Thursday, March 17th 

Registration: Please contact your Oppenheimer representation 

Maxim’s 2022 Virtual Growth Conference 

Presentation: Monday, March 28th to Wednesday, March 30th 

Registration: Click here

For more information about each conference, or to schedule a one-on-one meeting with Awakn’s management team, please contact your ROTH, Oppenheimer or Maxim representatives, or alternatively KCSA Strategic Communications at  

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction. Awakn's team consists of renowned research experts and world leading chemists, scientists, psychiatrists, and psychologists. Addiction is one of the biggest unmet medical needs of our time, affecting over 20% of the global population and is an industry valued at over $100bn per annum. Awakn is disrupting this underperforming industry by rapidly advancing the next generation of psychedelic drugs and therapies to be used in combination, through preclinical research and clinical stage trials.  |  Twitter  |  LinkedIn  |  Facebook

Investor Enquiries:
KCSA Strategic Communications 
Valter Pinto / Tim Regan 
Phone: +1 (212) 896-1254

Media Enquiries:

America and Canada: KCSA Strategic Communications  
Anne Donohoe

Rest of World: ROAD Communications 
Paul Jarman / Nora Popova